カテゴリ： GlobalData, イスラエル, 企業調査

Teva Pharmaceutical Industries Ltd (TEVA)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Teva Pharmaceutical Industries Ltd (TEVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012236
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：345
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イスラエル
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Teva Pharmaceutical Industries Ltd (Teva) carries out the research, development, manufacture and commercialization of generic and specialty medicines. It provides specialty medicines in central nervous system (CNS), respiratory, cancer, women’s health and other therapy areas. The company offers generic medicines in a range of dosage forms, including capsules, tablets, injectables, liquids, inhalants, creams and ointments. Teva also provides over-the-counter (OTC) products, as well as active pharmaceutical ingredients (APIs), the essential raw materials to the drug manufacturing industry. It carries out OTC business principally through PGT Healthcare, a consumer healthcare joint venture with The Procter & Gamble Company (P&G). The company conducts its worldwide operations through a network of global subsidiaries. Teva is headquartered in Petach Tikva, Israel.

Teva Pharmaceutical Industries Ltd (TEVA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 8
List of Figures 11
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 12
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 13
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 14
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 15
Teva Pharmaceutical Industries Ltd, Medical Devices Deals, 2011 to YTD 2017 17
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 18
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deal Details 29
Asset Purchase 29
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 29
Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 30
Labrys Biologics Acquires RN-307 from Pfizer 32
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million 33
Cephalon To Acquire Assets Related To Larazotide Acetate From Alba Therapeutics 35
Venture Financing 36
Auspex Pharma Raises US$20 Million In Series E Financing 36
Labrys Biologics Raises US$31 Million In Series A Financing 38
Auspex Pharma Raises US$25 Million In Series D Financing 40
Auspex Pharma Raises US$1.5 Million In Venture Financing 41
Gamida Cell Raises US$10 Million In Series E Financing 42
Teva Pharma Industries Invests In MultiGene Vascular Systems 44
SymBio Pharma Secures US$24.5 Million In Series E Financing Round 45
Private Equity 46
CVC Capital Partners to Acquire Women Health Portfolio from Teva Pharma for USD703 Million 46
Partners In Life Sciences Acquires Manufacturing Facility In Mitry-Mory From Cephalon 48
Partnerships 49
Teva Pharma May Form Joint Venture with Guangzhou Pharma 49
Teva Pharma and Nuvelution Pharma Enter into Agreement 50
AbCellera Biologics Enters into Research Agreement with Teva Pharma 51
Teva Pharma Enters into Distribution Agreement with Celltrion 52
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 53
Teva Pharma and Takeda Pharma Form Joint Venture 54
Teva Pharma Enters into Research Agreement with AbCellera Biologics 56
Egalet Enters into Agreement with Teva Pharma 57
Teva Pharma Partners with University College London and Imanova 58
Teva Pharma Enters into an Agreement with Microchips Biotech 59
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma 60
Venus Remedies Enters into Agreement with Teva Pharma for Anti Cancer Drug 61
Abic Marketing Enters into Agreement with Arena Pharma 62
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems 63
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 64
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 65
Champions Enters Into Drug Discovery And Development Agreement With Teva 66
Teva Pharma Plans To Enter Into Partnerships 67
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 68
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 69
Teva Pharma To Form Joint Venture With Handok Pharma 71
Teva Pharma Enters Into Co-Marketing Agreement With CTC Bio For Sildenafil 72
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax 73
Teva Pharma And Proctor & Gamble Finalize Joint Venture 74
Teva Pharma Forms Joint Venture With Procter & Gamble 75
Teva Pharma Enters Into Co-Development Agreement With Cocrystal Discovery 77
NeuroSearch Plans To Enter Into Co-Development Agreement For Tesofensine 78
NeuroSearch Extends Research Agreement With Janssen Pharmaceutica 79
ERYtech Pharma Enters into Distribution Agreement With Teva For Graspa 80
Champions Biotech Enters Into An Agreement With Cephalon 81
Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra 82
Celator Pharma Extends Research Agreement With Cephalon 83
Licensing Agreements 84
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 84
Teva Pharma Enters into Licensing Agreement with Takeda for Attenukine 85
Teva Pharma Enters into Licensing Agreement with CSPC Zhongqi Pharma 86
Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon 87
Teva Pharma Amends Licensing Agreement with Eagle Pharma for EP-3102 88
Auspex Pharma Enters into Licensing Agreement with Imphar 89
Xenon Pharma Enters Into Licensing Agreement With Teva Pharma For XEN402 90
Pierre Fabre Enters into Licensing Agreement with Medis 92
Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics 93
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 94
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 95
QRxPharma Enters Into Licensing Agreement With Teva Pharma For Moxduo 97
BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig 99
Sinclair IS Pharma Enters Into Licensing Agreement With Teva Pharma For episil 100
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine 101
Lundbeck Enters Into Licensing Agreement With Cephalon 102
APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI 103
ImmunGene Enters Into Licensing Agreement With Cephalon 104
Equity Offering 105
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 105
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 107
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 109
American Well Raises USD10 Million in Private Placement of Shares 111
Ignyta Raises USD42 Million in Private Placement of Shares 112
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares 113
Auspex Pharma Raises USD69.7 Million in Public Offering of Shares 115
Auspex Pharma Completes IPO For US$96.6 Million 117
Debt Offering 119
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 119
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 121
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 123
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 125
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 127
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 129
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 131
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 133
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 135
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 137
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 139
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 141
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 143
Teva Pharma Raises USD1.4 Billion in Public Offering of 1.25% Senior Notes Due 2023 144
Teva Pharma Raises USD760 Million in Public Offering of 1.875% Senior Notes Due 2027 145
Teva Pharma Completes Public Offering Of Notes Due 2020 For US$700 Million 146
Teva Pharma Completes Public Offering Of Notes Due 2022 For US$1.3 Billion 148
Teva Pharma Completes Public Offering Of Senior Notes Due 2018 For US$495 Million 150
Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For US$1.3 Billion 152
Teva Pharma Completes Public Offering Of 3.65% Senior Notes Due 2021 For US$875 Million 154
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$200 Million 156
Teva Pharma Completes Public Offering Of Notes Due 2021 For US$875 Million 158
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$1.1 Billion 160
Teva Pharma Completes Public Offering Of 2.4% Senior Notes Due 2016 For US$950 Million 162
Teva Pharma Completes Public Offering Of 1.7% Senior Notes Due 2014 For US$1 Billion 164
Teva Pharma Completes Public Offering Of Senior Notes Due 2014 For US$250 Million 166
Teva Pharma Completes Public Offering Of Senior Notes Due 2014 For US$500 Million 167
Asset Transactions 168
Foundation Consumer Healthcare Acquires Women Health Products from Teva Pharma for USD675 Million 168
Teva Pharma May Sell European Oncology and Pain Assets 170
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 171
Teva Pharma May sell Medis Unit 172
OncBioMune Pharma Acquire Norepinefrine in Mexico from Teva Pharma 173
Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare 174
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 176
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million 177
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 178
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 180
Dr. Reddy’s Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 182
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 183
Perrigo Acquires Remaining 60.9% Rights of Benzaclin from Barr Labs for USD62 Million 184
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire 185
Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma 186
Saniona Acquires ACR325 and ACR343 Drugs from NeuroSearch 187
Teva Pharma May Divest its Assets 188
Ferring Pharma Acquires Global Rights to Milprosa from Teva Women’s Health 190
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 191
Teva Pharma Plans to Divest Some Operations 192
Ignyta Acquires Four Oncology R&D Assets from Cephalon 193
ANI Pharma Acquires ANDA from Teva Pharma 195
Teva Pharma to Sell its Manufacturing Facility in Sellersville, Pennsylvania to G&W Labs 196
Saniona Acquires Rights of Tesofensine from NeuroSearch 197
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 198
Amedra Pharmaceuticals Acquires Mebendazole Tablet Product from Teva Pharmaceutical 199
Teva Pharma Plans To Sell Manufacturing Facility In Irvine, California 200
CleveXel Pharma Acquires Development Center From Teva Pharma 201
Procter & Gamble Receives EC Approval To Acquire OTC Business Of Teva Pharma 202
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million 203
Aniona Acquires Portfolio of Preclinical Assets from NeuroSearch 205
Halo Pharma Completes Acquisition Of Mirabel Manufacturing Facility From Teva Canada 206
Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma 207
Acquisition 209
NeuroSearch Plans to Sell Itself 209
Allergan to Sell 10% Stake in Teva Pharma 210
Teva Pharma Sells Stake in Mesoblast 211
Clal Biotech to Acquire 5% Stake in Gamida Cell from Teva Pharma 212
Teva Pharma Acquires Anda from Allergan for USD500 Million 213
Teva Pharma, Mylan May Acquire Teut|Pfizer 214
Teva Pharma Acquires Rimsa for USD2.3 Billion 216
Auspex Pharma Acquires Imphar 217
Teva Pharma to Acquire Gecko Health Innovations 218
Teva Pharma to Acquire 51% Stake in Immuneering 219
Teva Pharma Acquires Auspex Pharma 220
Ind-Swift Lab May Sell Stake in Company 222
Teva Pharma Completes Acquisition of Labrys Biologics 223
Teva Pharma Completes Acquisition Of NuPathe For US$144 Million In Tender Offer 224
Teva Pharma Completes Acquisition of MicroDose Therapeutx 226
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 227
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 229
XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million 231
Teva Pharma Rumored To Acquire Amarin 232
Teva Completes Acquisition Of Cephalon For US$6,800 Million 233
Teva Pharma Acquires Remaining 50% Stake In Teva-Kowa Pharma For US$150 Million 235
Biolin Scientific Acquires Sophion Bioscience 236
Teva Pharma Invests Additional US$19 Million In CureTech 238
Teva Pharma Industries Acquires Taiyo Pharma Industry 239
Cephalon Acquires 91.73% Stake In ChemGenex 241
Cephalon Acquires Gemin X Pharma 243
Clal Biotech Acquires Stake In TransPharma Medical From Teva 245
Cephalon Completes Acquisition Of 20% Stake In Mesoblast 246
Teva Pharma Industries Acquires Corporacion Infarmasa 248
Teva Pharma Industries Acquires THERAMEX From Merck Serono 249
Teva Pharmaceutical Industries Ltd – Key Competitors 251
Teva Pharmaceutical Industries Ltd – Key Employees 252
Teva Pharmaceutical Industries Ltd – Locations And Subsidiaries 253
Head Office 253
Other Locations & Subsidiaries 253
Joint Venture 261
Recent Developments 262
Strategy And Business Planning 262
Mar 31, 2016: Takeda and Teva Establish “Teva Takeda Yakuhin” in Japan 262
Feb 24, 2016: Teva Pharmaceuticals Embarks on Strategic Corporate Identity Program to Build a Global Brand 263
Financial Announcements 264
Nov 02, 2017: Teva Reports Third Quarter 2017 Financial Results 264
Aug 03, 2017: Teva Reports Second Quarter 2017 Financial Results 268
May 11, 2017: Teva Reports First Quarter 2017 Financial Results 270
Feb 13, 2017: Teva Reports Full Year and Fourth Quarter 2016 Financial Results 274
Jan 06, 2017: Teva Provides 2017 Financial Outlook 282
Nov 15, 2016: Teva Reports Third Quarter 2016 Results 284
Aug 04, 2016: Teva Reports Second Quarter 2016 Results 286
May 09, 2016: Teva Reports First Quarter 2016 Results 290
Feb 11, 2016: Teva Reports Full Year 2015 and Fourth Quarter Financial Results 294
Corporate Communications 300
Oct 30, 2017: Kare Schultz to Join Teva as President and Chief Executive Officer 300
Sep 11, 2017: Teva Names Kare Schultz as President and Chief Executive Officer 301
Jul 23, 2017: Teva to Terminate Around 300 jobs in Israel 303
Jul 13, 2017: Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders 304
Apr 26, 2017: Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer 305
Feb 06, 2017: Teva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez Vigodman 306
Dec 05, 2016: Teva Appoints Dipankar Bhattacharjee as President and Chief Executive Officer, Global Generic Medicines Group, Succeeding Siggi Olafsson 308
Nov 08, 2016: Teva Announces Appointment of New Chief Legal Officer 310
Oct 17, 2016: Teva receives positive opinion from EMA’s CHMP to extend indication of Trisenox for APL treatment 311
Jan 25, 2016: Teva Releases Innovation and Social Responsibility Highlights 312
Legal and Regulatory 313
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 313
Dec 22, 2016: Teva Reaches Settlement with Government on FCPA 314
Dec 22, 2016: Teva Pharmaceutical Paying $519 Million to Settle FCPA Charges 315
Aug 25, 2016: Teva Plunges After Two U.S. Copaxone Patents Invalidated 316
Product News 318
11/07/2016: Teva Presents Data on Beclomethasone dipropionate at the 2016 American College of Allergy, Asthma & Immunology Annual Scientific Meeting 318
10/12/2016: Teva Announces Launch of Generic Beyaz in the United States 319
06/20/2016: Teva to Present Data Highlighting SD-809 at 20th International Congress of Parkinson’s Disease and Movement Disorders 320
06/08/2016: New drug to prevent migraine may start working in days 321
05/17/2017: Teva Announces Presentation on Beclomethasone Dipropionate at the 2017 American Thoracic Society (ATS) International Conference 322
05/17/2017: Teva to Present Data for Deutetrabenazine in Tardive Dyskinesia at the American Psychiatric Association 2017 Annual Meeting 323
04/27/2017: Teva Announces Publication of ARM-TD Study Results in Neurology for the Investigational Use of Deutetrabenazine in Tardive Dyskinesia 324
04/12/2016: Teva to Present Data on SD-809 (deutetrabenazine) at 68th AAN Annual Meeting 325
04/12/2016: Teva to Present Data on TEV-48125 at 68th AAN Annual Meeting 326
04/03/2017: Teva Announces FDA Approval of AUSTEDO (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease 327
02/28/2017: Teva Announces Priority Review Granted by FDA for SD-809 for Treatment of Tardive Dyskinesia 328
Product Approvals 329
Oct 20, 2016: Teva Announces FDA Acceptance of Resubmitted New Drug Application for SD-809 for Treatment of Chorea Associated with Huntington Disease 329
May 31, 2016: Teva Receives Complete Response Letter for NDA for SD-809 for the Treatment of Chorea Associated with Huntington Disease 330
Clinical Trials 331
Jul 11, 2017: Teva and the Huntington Study Group Announce Publication of Data for AUSTEDO (deutetrabenazine) Tablets in Huntington Disease from ARC-HD Study in JAMA Neurology 331
Jun 29, 2017: Teva Announces Publication of AIM-TD Study Results in The Lancet Psychiatry for the Investigational Use of Deutetrabenazine in Tardive Dyskinesia 332
Jun 01, 2017: Teva to Present Data on Deutetrabenazine at the 21st International Congress of Parkinson’s Disease and Movement Disorders 333
Apr 19, 2017: Teva to Present Data on Deutetrabenazine at 69th Annual Meeting of the American Academy of Neurology 335
Apr 05, 2017: URMC Plays Key Role in New Huntington’s Drug 336
Sep 22, 2016: Teva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD) 337
Jul 05, 2016: Teva and the Huntington Study Group Announce Publication of Pivotal Phase III Data on Deutetrabenazine (SD-809) in Huntington Disease from First-HD Trial in JAMA 338
Apr 18, 2016: Teva Presents New Data for SD-809 in Huntington Disease at 68th American Academy of Neurology Annual Meeting in Vancouver, B.C. 339
Jan 11, 2016: Active Biotech: Information regarding the clinical study LEGATO-HD 340
Jan 04, 2016: Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials 341
Other Significant Developments 342
Oct 19, 2017: Teva: New Belief-based Patient Support Programme (PSP) Launched for People With Relapsing Multiple Sclerosis 342
Jul 15, 2016: PhRMA Welcomes Five New Member Companies 344
Appendix 345
Methodology 345
About GlobalData 345
Contact Us 345
Disclaimer 345

List of Tables
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 12
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 13
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 14
Teva Pharmaceutical Industries Ltd, Deals By Therapy Area, 2011 to YTD 2017 15
Teva Pharmaceutical Industries Ltd, Medical Devices Deals, 2011 to YTD 2017 17
Teva Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 18
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 29
Teva Pharma Acquires Generics Drug Business from Allergan for USD39 Billion 30
Labrys Biologics Acquires RN-307 from Pfizer 32
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million 33
Cephalon To Acquire Assets Related To Larazotide Acetate From Alba Therapeutics 35
Auspex Pharma Raises US$20 Million In Series E Financing 36
Labrys Biologics Raises US$31 Million In Series A Financing 38
Auspex Pharma Raises US$25 Million In Series D Financing 40
Auspex Pharma Raises US$1.5 Million In Venture Financing 41
Gamida Cell Raises US$10 Million In Series E Financing 42
Teva Pharma Industries Invests In MultiGene Vascular Systems 44
SymBio Pharma Secures US$24.5 Million In Series E Financing Round 45
CVC Capital Partners to Acquire Women Health Portfolio from Teva Pharma for USD703 Million 46
Partners In Life Sciences Acquires Manufacturing Facility In Mitry-Mory From Cephalon 48
Teva Pharma May Form Joint Venture with Guangzhou Pharma 49
Teva Pharma and Nuvelution Pharma Enter into Agreement 50
AbCellera Biologics Enters into Research Agreement with Teva Pharma 51
Teva Pharma Enters into Distribution Agreement with Celltrion 52
Regeneron Pharma Enters into Co-Development Agreement with Teva Pharma for Fasinumab 53
Teva Pharma and Takeda Pharma Form Joint Venture 54
Teva Pharma Enters into Research Agreement with AbCellera Biologics 56
Egalet Enters into Agreement with Teva Pharma 57
Teva Pharma Partners with University College London and Imanova 58
Teva Pharma Enters into an Agreement with Microchips Biotech 59
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma 60
Venus Remedies Enters into Agreement with Teva Pharma for Anti Cancer Drug 61
Abic Marketing Enters into Agreement with Arena Pharma 62
Teva Pharma Industries to Form Joint Venture with Philips Medical Systems 63
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 64
Cancer Research Technology And Teva Enter Into R&D Agreement To Develop Cancer Drugs 65
Champions Enters Into Drug Discovery And Development Agreement With Teva 66
Teva Pharma Plans To Enter Into Partnerships 67
Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide 68
Teva Pharma Enters Into Co-Marketing Agreement With Verinata Health For Verifi Test 69
Teva Pharma To Form Joint Venture With Handok Pharma 71
Teva Pharma Enters Into Co-Marketing Agreement With CTC Bio For Sildenafil 72
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax 73
Teva Pharma And Proctor & Gamble Finalize Joint Venture 74
Teva Pharma Forms Joint Venture With Procter & Gamble 75
Teva Pharma Enters Into Co-Development Agreement With Cocrystal Discovery 77
NeuroSearch Plans To Enter Into Co-Development Agreement For Tesofensine 78
NeuroSearch Extends Research Agreement With Janssen Pharmaceutica 79
ERYtech Pharma Enters into Distribution Agreement With Teva For Graspa 80
Champions Biotech Enters Into An Agreement With Cephalon 81
Teva Pharma Industries Enters Into Co-Development Agreement With Alcobra 82
Celator Pharma Extends Research Agreement With Cephalon 83
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 84
Teva Pharma Enters into Licensing Agreement with Takeda for Attenukine 85
Teva Pharma Enters into Licensing Agreement with CSPC Zhongqi Pharma 86
Checkpoint Therapeutics Enters into Licensing Agreement with Cephalon 87
Teva Pharma Amends Licensing Agreement with Eagle Pharma for EP-3102 88
Auspex Pharma Enters into Licensing Agreement with Imphar 89
Xenon Pharma Enters Into Licensing Agreement With Teva Pharma For XEN402 90
Pierre Fabre Enters into Licensing Agreement with Medis 92
Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics 93
Intellipharmaceutics Enters into Licensing Agreement with Teva Pharma 94
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 95
QRxPharma Enters Into Licensing Agreement With Teva Pharma For Moxduo 97
BioAlliance Pharma Enters Into Licensing Agreement With Teva Pharma For Sitavig 99
Sinclair IS Pharma Enters Into Licensing Agreement With Teva Pharma For episil 100
CEL-SCI Expands Licensing Agreement With Teva Pharma For Multikine 101
Lundbeck Enters Into Licensing Agreement With Cephalon 102
APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI 103
ImmunGene Enters Into Licensing Agreement With Cephalon 104
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 105
Teva Pharma Announces Underwriters Exercise of Over-Allotment of American Depositary Shares 107
Teva Pharma Announces Underwriters Exercise of Over-Allotment of Preferred Shares 109
American Well Raises USD10 Million in Private Placement of Shares 111
Ignyta Raises USD42 Million in Private Placement of Shares 112
Auspex Pharma Raises USD203.4 Million in Public Offering of Shares 113
Auspex Pharma Raises USD69.7 Million in Public Offering of Shares 115
Auspex Pharma Completes IPO For US$96.6 Million 117
Teva Pharma Raises USD304 Million in Public Offering of 0.125% Notes Due 2018 119
Teva Pharma Raises USD354.6 Million in Public Offering of 1% Notes Due 2025 121
Teva Pharma Raises USD354.6 Million in Public Offering of 0.5% Notes Due 2022 123
Teva Pharma Raises USD1.65 Billion in Additional Public Offering of 1.125% Notes Due 2024 125
Teva Pharma Raises USD1.93 Billion in Additional Public Offering of 0.375% Notes Due 2020 127
Teva Pharma Raises USD820 Million in Additional Public Offering of 1.625% Notes Due 2028 129
Teva Pharma Raises USD3 Billion in Public Offering of 2.8% Notes Due 2023 131
Teva Pharma Raises USD1.5 Billion in Public Offering of 1.4% Notes Due 2018 133
Teva Pharma Raises USD2 Billion in Public Offering of 1.7% Notes Due 2019 135
Teva Pharma Raises USD2 Billion in Public Offering of 4.1% Notes Due 2046 137
Teva Pharma Raises USD3.5 Billion in Public Offering of 3.15% Notes Due 2026 139
Teva Pharma Raises USD3 Billion in Public Offering of 2.2% Notes Due 2021 141
Teva Pharma Plans to Raise USD22 Billion in Public Offering of Bonds 143
Teva Pharma Raises USD1.4 Billion in Public Offering of 1.25% Senior Notes Due 2023 144
Teva Pharma Raises USD760 Million in Public Offering of 1.875% Senior Notes Due 2027 145
Teva Pharma Completes Public Offering Of Notes Due 2020 For US$700 Million 146
Teva Pharma Completes Public Offering Of Notes Due 2022 For US$1.3 Billion 148
Teva Pharma Completes Public Offering Of Senior Notes Due 2018 For US$495 Million 150
Teva Pharma Completes Public Offering Of Senior Notes Due 2019 For US$1.3 Billion 152
Teva Pharma Completes Public Offering Of 3.65% Senior Notes Due 2021 For US$875 Million 154
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$200 Million 156
Teva Pharma Completes Public Offering Of Notes Due 2021 For US$875 Million 158
Teva Pharma Completes Public Offering Of Floating Rate Senior Notes Due 2013 For US$1.1 Billion 160
Teva Pharma Completes Public Offering Of 2.4% Senior Notes Due 2016 For US$950 Million 162
Teva Pharma Completes Public Offering Of 1.7% Senior Notes Due 2014 For US$1 Billion 164
Teva Pharma Completes Public Offering Of Senior Notes Due 2014 For US$250 Million 166
Teva Pharma Completes Public Offering Of Senior Notes Due 2014 For US$500 Million 167
Foundation Consumer Healthcare Acquires Women Health Products from Teva Pharma for USD675 Million 168
Teva Pharma May Sell European Oncology and Pain Assets 170
Intas Pharma and Aurobindo Pharma May Acquire Europen Divisions from Teva Pharma 171
Teva Pharma May sell Medis Unit 172
OncBioMune Pharma Acquire Norepinefrine in Mexico from Teva Pharma 173
Teva Pharma Sells Assets and Operations of Actavis Generics in UK and Ireland to Accord Healthcare 174
Arrow Generiques to Acquire Select Commercial Products in France from Teva Pharma 176
Sagent Pharma Acquires Product Portfolio from Teva Pharma and Actavis for USD40 Million 177
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 178
Impax Labs Acquires Generic Products from Teva Pharma and Allergan for USD586 Million 180
Dr. Reddy’s Labs Acquires Portfolio of Eight ANDAs from Teva Pharma for USD350 Million 182
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 183
Perrigo Acquires Remaining 60.9% Rights of Benzaclin from Barr Labs for USD62 Million 184
Prasco to Acquire Authorized Generic of Adderall XR Capsules from Teva Pharma and Shire 185
Zydus Cadila Healthcare Announces Acquisition of Two Abbreviated New Drug Applications form Teva Pharma 186
Saniona Acquires ACR325 and ACR343 Drugs from NeuroSearch 187
Teva Pharma May Divest its Assets 188
Ferring Pharma Acquires Global Rights to Milprosa from Teva Women's Health 190
ANI Pharma Acquires Rights to Testosterone Gel 1% from Teva Pharma 191
Teva Pharma Plans to Divest Some Operations 192
Ignyta Acquires Four Oncology R&D Assets from Cephalon 193
ANI Pharma Acquires ANDA from Teva Pharma 195
Teva Pharma to Sell its Manufacturing Facility in Sellersville, Pennsylvania to G&W Labs 196
Saniona Acquires Rights of Tesofensine from NeuroSearch 197
ANI Pharma Acquires 22 Generic Drug Products from Teva Pharma 198
Amedra Pharmaceuticals Acquires Mebendazole Tablet Product from Teva Pharmaceutical 199
Teva Pharma Plans To Sell Manufacturing Facility In Irvine, California 200
CleveXel Pharma Acquires Development Center From Teva Pharma 201
Procter & Gamble Receives EC Approval To Acquire OTC Business Of Teva Pharma 202
Teva Completes Acquisition Of Huntexil Development Program Rights From NeuroSearch For US$26 Million 203
Aniona Acquires Portfolio of Preclinical Assets from NeuroSearch 205
Halo Pharma Completes Acquisition Of Mirabel Manufacturing Facility From Teva Canada 206
Par Pharma Acquires Rights And Assets To Three Products From Teva Pharma 207
NeuroSearch Plans to Sell Itself 209
Allergan to Sell 10% Stake in Teva Pharma 210
Teva Pharma Sells Stake in Mesoblast 211
Clal Biotech to Acquire 5% Stake in Gamida Cell from Teva Pharma 212
Teva Pharma Acquires Anda from Allergan for USD500 Million 213
Teva Pharma, Mylan May Acquire Teut|Pfizer 214
Teva Pharma Acquires Rimsa for USD2.3 Billion 216
Auspex Pharma Acquires Imphar 217
Teva Pharma to Acquire Gecko Health Innovations 218
Teva Pharma to Acquire 51% Stake in Immuneering 219
Teva Pharma Acquires Auspex Pharma 220
Ind-Swift Lab May Sell Stake in Company 222
Teva Pharma Completes Acquisition of Labrys Biologics 223
Teva Pharma Completes Acquisition Of NuPathe For US$144 Million In Tender Offer 224
Teva Pharma Completes Acquisition of MicroDose Therapeutx 226
Celltrion Chairman Jung Jin Seo Plans To Sell Controlling Stake In The Company 227
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 229
XTL Biopharma Acquires 31% Stake In Proteologics From Teva For US$2 Million 231
Teva Pharma Rumored To Acquire Amarin 232
Teva Completes Acquisition Of Cephalon For US$6,800 Million 233
Teva Pharma Acquires Remaining 50% Stake In Teva-Kowa Pharma For US$150 Million 235
Biolin Scientific Acquires Sophion Bioscience 236
Teva Pharma Invests Additional US$19 Million In CureTech 238
Teva Pharma Industries Acquires Taiyo Pharma Industry 239
Cephalon Acquires 91.73% Stake In ChemGenex 241
Cephalon Acquires Gemin X Pharma 243
Clal Biotech Acquires Stake In TransPharma Medical From Teva 245
Cephalon Completes Acquisition Of 20% Stake In Mesoblast 246
Teva Pharma Industries Acquires Corporacion Infarmasa 248
Teva Pharma Industries Acquires THERAMEX From Merck Serono 249
Teva Pharmaceutical Industries Ltd, Key Competitors 251
Teva Pharmaceutical Industries Ltd, Key Employees 252
Teva Pharmaceutical Industries Ltd, Subsidiaries 253
Teva Pharmaceutical Industries Ltd, Joint Venture 261

★海外企業調査レポート[Teva Pharmaceutical Industries Ltd (TEVA)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Essar Power Ltd：企業の戦略的SWOT分析
    Essar Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Bank of China Ltd：戦略・SWOT・企業財務分析
    Bank of China Ltd - Strategy, SWOT and Corporate Finance Report Summary Bank of China Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Median Technologies SA (ALMDT)：医療機器：M&Aディール及び事業提携情報
    Summary Median Technologies SA (Median) is a medical technology company that develops and markets medical imaging solutions. The company offers clinical trials, imaging services for CT, scientific consulting, image and clinical data management, image data processing and site support, managed service …
  • Avenue Therapeutics Inc (ATXI)：製薬・医療：M&Aディール及び事業提携情報
    Summary Avenue Therapeutics Inc (Avenue Therapeutics), a subsidiary of Fortress Biotech Inc, is a specialty pharmaceutical company that focuses on the development and commercialization of an intravenous (IV) tramadol for the management of severe postoperative pain in adults. The company’s IV Tramado …
  • Theralase Technologies Inc (TLT)：医療機器：M&Aディール及び事業提携情報
    Summary Theralase Technologies Inc (Theralase Technologies) is a biopharmaceutical company that manufactures, designs, and develops laser and laser technology for companion animal, human, and equine applications. The company offers products such as multiple probe, controller, multiple probe, triple …
  • The Clorox Company (CLX)：企業の財務・戦略的SWOT分析
    The Clorox Company (CLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Immunodiagnostic Systems Holdings plc (IDH)：医療機器：M&Aディール及び事業提携情報
    Summary Immunodiagnostic Systems Holdings plc (IDS) is an in-vitro diagnostic solution provider that develops, manufactures and markets immunoassays and automated immunoanalyser technologies. The company conducts research in the areas of bone turnover market, animal research, and other research area …
  • Dunelm Group plc (DNLM)：企業の財務・戦略的SWOT分析
    Dunelm Group plc (DNLM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Power Finance Corporation Ltd.：企業の戦略・SWOT・財務分析
    Power Finance Corporation Ltd. - Strategy, SWOT and Corporate Finance Report Summary Power Finance Corporation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Portland General Electric Co (POR)：企業の財務・戦略的SWOT分析
    Portland General Electric Co (POR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Salk Institute for Biological Studies-製薬・医療分野：企業M&A・提携分析
    Summary Salk Institute for Biological Studies (Salk) is a research institute that offers biological research programs. The institute’s areas of research comprise molecular biology and genetics, neurosciences, and plant biology. Its research provides development of new therapies and treatments for di …
  • 4P-Pharma SAS-製薬・医療分野：企業M&A・提携分析
    Summary 4P-Pharma SAS (4P-Pharma) focuses on the development of novel therapies for the treatment of cancer and inflammatory diseases. The company’s pipeline product portfolio includes new chemical entities, biologics, added value generics and fixed dose combinations. Its pipeline candidates targets …
  • Nigeria LNG Ltd：企業の戦略的SWOT分析
    Nigeria LNG Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • A&R Carton AB：企業の戦略・SWOT・財務情報
    A&R Carton AB - Strategy, SWOT and Corporate Finance Report Summary A&R Carton AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • P. H. Glatfelter Co (GLT)：企業の財務・戦略的SWOT分析
    P. H. Glatfelter Co (GLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Kuwait Reinsurance Company K.S.C.C.：企業の戦略・SWOT・財務情報
    Kuwait Reinsurance Company K.S.C.C. - Strategy, SWOT and Corporate Finance Report Summary Kuwait Reinsurance Company K.S.C.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • ABX Advanced Biochemical Compounds GmbH：製薬・医療：M&Aディール及び事業提携情報
    Summary ABX Advanced Biochemical Compounds GmbH (ABX), a subsidiary of Otsuka Holdings Co Ltd is a provider of biochemical compounds that manufactures, develops, and distributes biochemicals for nuclear medicine. The company provides products such as PET and SPECT precursors and reference standards, …
  • Flexion Therapeutics Inc (FLXN)：企業の財務・戦略的SWOT分析
    Flexion Therapeutics Inc (FLXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Siemens Medical Solutions USA Inc：企業のM&A・事業提携・投資動向
    Siemens Medical Solutions USA Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Siemens Medical Solutions USA Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Seoul City Gas Co Ltd (017390)：企業の財務・戦略的SWOT分析
    Seoul City Gas Co Ltd (017390) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆